Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 10/20 | 0.52 |
| ▸ | MMP13 | P45452 | 9/20 | 0.52 |
| ▸ | MMP1 | P03956 | 10/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 7/20 | 0.50 |
| ▸ | MMP2 | P08253 | 5/20 | 0.41 |
| ▸ | MMP3 | P08254 | 4/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL7553524 | 0.84 | MMP13 (0.51) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL6934202 | 0.83 | MMP13 (0.53) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL27512626 | 0.77 | MMP13 (0.75) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL6928813 | 0.71 | MMP9 (0.57) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL6932142 | 0.71 | MMP9 (0.51) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL6929323 | 0.68 | MMP13 (1.00) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL8714771 | 0.68 | MMP13 (0.73) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL7996966 | 0.67 | MMP9 (0.53) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL7324090 | 0.67 | MMP13 (0.71) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL6930723 | 0.67 | MMP13 (0.82) | MMP9MMP13MMP1ADAM17MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | MMP9 16/4885MMP13 15/4885MMP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.